ATM and plasma cell myeloma: In other work, human multiple myeloma (MM) cells were treated with MEDI2228, a ligand of the B-cell maturation antigens that induces ATM/ATR-Chk1/2 pathway activation, in combination with different inhibitors of the principal kinases of the DDR (ATM, ATR, and WEE1) (66).